Regeneron Takes Full Libtayo Rights As March Into Oncology Progresses
Executive Summary
The company will pay $900m upfront to buy Sanofi's stake in the PD-1 inhibitor, which is a cornerstone of Regeneron's strategy to build an oncology portfolio.
You may also be interested in...
CytomX Bounces Back From Trial Setback With Regeneron Bispecific Antibody Partnership
The US biotech has nabbed a deal with Regeneron to develop bispecific cancer therapies by combining their respective technology platforms, getting $30m upfront in a positive twist of fate following a recent clinical trial challenge.
Libtayo Gains Approval for First-Line NSCLC With Chemotherapy
Regeneron's PD-1 inhibitor was approved by the US FDA in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer.
Regeneron’s Oncology Strategy Gets Warmer With Early Prostate Data
The costimulatory bispecific antibody REGN5678, meant to turn “cold” prostate cancer tumors “hot” and vulnerable to PD-1 inhibitors, showed early signs of efficacy combined with Libtayo.